1 Ocak 2021 Dergi makalesi Açık Erişim

Yakubogullari, Nilgun; Coven, Furkan Ozan; Cebi, Nusin; Coven, Fethiye; Coven, Nejdet; Genc, Rukan; Bedir, Erdal; Nalbantsoy, Ayse

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Yakubogullari, Nilgun</dc:creator>
  <dc:creator>Coven, Furkan Ozan</dc:creator>
  <dc:creator>Cebi, Nusin</dc:creator>
  <dc:creator>Coven, Fethiye</dc:creator>
  <dc:creator>Coven, Nejdet</dc:creator>
  <dc:creator>Genc, Rukan</dc:creator>
  <dc:creator>Bedir, Erdal</dc:creator>
  <dc:creator>Nalbantsoy, Ayse</dc:creator>
  <dc:date>2021-01-01</dc:date>
  <dc:description>Astragaloside VII (AST-VII), a major cycloartane saponin isolated from Turkish Astragalus species, turned out to be one of the most active metabolites demonstrating Th1/Th2 balanced immune response. As Quillaja saponins are extensively used in adjuvant systems, this study made an attempt to improve AST-VII based adjuvant systems by using different immunostimulatory/delivery agents (monophosphoryllipid A (MPL), Astragalus polysaccharide (APS) and squalene) and to induce cellular and humoral immune response against a viral vaccine. For this purpose, Newcastle Disease vaccine (NDV) was chosen as a model vaccine. Swiss albino mice were immunized subcutaneously with LaSota vaccines in the presence/absence of AST-VII or developed adjuvant systems. AST-VII administration both in live/inactivated LaSota vaccines induced neutralizing and NDV specific IgG, IgG1 and IgG2b antibodies response as well as IL-2 and IL-4 production. APS based delivery systems enhanced the production of neutralizing antibody and the minor augmentation of IFN-? and IL-2 levels. Squalene emulsion (SE) alone or combined with AST-VII were effective in NDV restimulated splenocyte proliferation. As a conclusion, AST-VII and AST-VII containing adjuvant systems demonstrated Th1/Th2 balanced antibody and cellular immune responses in NDV vaccines. Thus, these systems could be developed as vaccine adjuvants in viral vaccines as alternative to saponin-based adjuvants.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/233224</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:233224</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>BIOLOGICALS 70 28-37</dc:source>
  <dc:title>Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>